Pfizer (NYSE:PFE) Shares Down 1.1% - Should You Sell?

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) fell 1.1% on Tuesday . The stock traded as low as $25.81 and last traded at $25.85. 8,437,133 shares changed hands during trading, a decline of 77% from the average session volume of 36,645,983 shares. The stock had previously closed at $26.14.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PFE shares. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a fifty day moving average price of $26.12 and a 200 day moving average price of $26.98. The stock has a market cap of $142.08 billion, a P/E ratio of 17.77, a P/E/G ratio of 0.64 and a beta of 0.61.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company's stock.

Institutional Trading of Pfizer

Several institutional investors have recently made changes to their positions in PFE. PSI Advisors LLC grew its position in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in shares of Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after buying an additional 391 shares during the last quarter. D Orazio & Associates Inc. grew its holdings in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares in the last quarter. Lipe & Dalton increased its position in shares of Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC lifted its holdings in Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after acquiring an additional 401 shares during the period. Institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.